GlassScriptPhysician profile
Joel Zachariah John
NPI 1306376595
$5,089.75
in general payments reported to CMS, 2019-2025
33 companies · $72.81 in 2025
The $72.81 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.00 · 2020: $324 · 2021: $1,731 · 2022: $1,726 · 2023: $844 · 2024: $294 · 2025: $72.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878 · Education: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $877.81 |
| Education | $333.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $1,437.50 | 2020-2023 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $420.28 | 2022-2025 | |
| Verathon INC. | $400.00 | 2021 | |
| Vifor Pharma, INC. | $380.18 | 2020-2022 | |
| Abbvie INC. | $273.05 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $266.91 | 2021-2023 | Jardiance |
| Corcept Therapeutics | $225.77 | 2022 | |
| Amgen INC. | $200.63 | 2020-2023 | Repatha |
| Novo Nordisk INC | $156.07 | 2021-2023 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $146.87 | 2023-2024 | |
| Dexcom, INC. | $125.00 | 2023 | Dexcom G7 Gss (161) |
| Allergan, INC. | $117.09 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $100.50 | 2021-2022 | |
| Viiv Healthcare Company | $98.00 | 2019 | |
| Lilly USA, LLC | $96.32 | 2021-2023 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $94.95 | 2024 | Cologuard Collection Kit |
| Mannkind Corporation | $70.79 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $60.76 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $58.93 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $48.48 | 2021-2022 | |
| Pfizer INC. | $44.60 | 2021-2022 | |
| Depuy Synthes Sales INC. | $43.07 | 2021 | |
| Intuity Medical INC | $37.84 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Travere Therapeutics, INC. | $29.08 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $23.57 | 2023 | Lupkynis |
| Ardelyx, INC. | $22.81 | 2023 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $18.37 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.34 | 2021 | |
| Ibsa Pharma INC. | $17.22 | 2021 | |
| Genzyme Corporation | $15.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.52 | 2022 | |
| Abbott Laboratories | $14.26 | 2024 | Mitraclip |
| Redhill Biopharma INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel John listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.